Click below for information IMM RNS Form TR1 Lanstead 1st September 2020

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an important regulatory milestone in preparation for the new optimised international Phase III trial of  Lupuzor™ for systemic lupus erythematosus (“SLE”) a potentially life-threatening auto-immune disease. ImmuPharma’s licensing partner for Lupuzor™, Avion Pharmaceuticals LLC (“Avion”), has submitted a Special Protocol…

ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed, by way of a poll. For full announcement click here

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company’s Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting…

ImmuPharma (LSE:IMM) (Euronext Growth Brussels: ALIMM), announces that on 11 June 2020, Dr Robert Zimmer, a Director of the Company, transferred 20,000,000 ordinary shares of 10 pence each (“Ordinary Shares”) to Luca & Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder. For full information click here

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, is pleased to announce that it has entered into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million (£4.94 million) comprising an issue of unsecured convertible securities (“Securities”) and associated options (“Options”).…

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (“MAR”).

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that the Company’s Annual General Meeting (AGM) confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19 Guidance rules still apply, as set out in the announcement issued on…

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2019, and the Notice of Annual General Meeting has been posted to shareholders. These documents are available, in electronic form, for download on the Company’s website…

Click here for information IMM RNS Form TR1 Lanstead 18 May 2020